Cyclooxygenase-2 Inhibitor: A Potential Combination Strategy With Immunotherapy in Cancer

被引：66

作者：

Pu, Dan ^{[1
]}

Yin, Liyuan ^{[1
]}

Huang, Lin ^{[1
]}

Qin, Changlong ^{[1
]}

Zhou, Yuwen ^{[2
]}

Wu, Qiang ^{[1
]}

Li, Yan ^{[1
]}

Zhou, Qinghua ^{[1
]}

Li, Lu ^{[1
]}

机构：

[1] Sichuan Univ, West China Hosp, Dept Lung Canc Ctr, Lung Canc Ctr, Chengdu, Peoples R China

[2] Sichuan Univ, West China Hosp, Dept Oncol, Chengdu, Peoples R China

来源：

FRONTIERS IN ONCOLOGY | 2021年 / 11卷

关键词：

cyclooxygenase-2; immunotherapy; cancer; combination therapy; celecoxib; CELL LUNG-CANCER; PHASE-II TRIAL; PD-L1; EXPRESSION; PROGNOSTIC VALUE; CELECOXIB; COX-2; BIOMARKER; BLOCKADE; DRIVEN;

D O I：

10.3389/fonc.2021.637504

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The clinical application of immunotherapy is the milestone of cancer treatment. However, some patients have bad reaction. Cyclooxygenase-2 (COX-2) is frequently expressed in multiple cancer cells and is associated with poor prognosis. It is the key enzyme of prostaglandin E-2 (PGE2) that has been proved to promote the development, proliferation and metastasis of tumor cells. Recent studies further find the PGE2 in tumor microenvironment (TME) actively triggers tumor immune evasion via many ways, leading to poor response of immunotherapy. COX-2 inhibitor is suggested to restrain the immunosuppression of PGE2 and may enhance or reverse the response of immune checkpoint inhibitors (ICIs). This review provides insight into the mechanism of COX-2/PGE2 signal in immunosuppressive TME and summarizes the clinical application and trials in cancer treatment.

引用

页数：7

共 50 条

[41] Antiproliferative effects of selective cyclooxygenase-2 inhibitor modulated by nimotuzumab in estrogen-dependent breast cancer cells
Wang, Ying-Xue
Gao, Jin-Xiang
Wang, Xiu-Yun
Zhang, Li
Liu, Chang-Mei
TUMOR BIOLOGY, 2012, 33 (04) : 957 - 966
[42] Antitumor activity of the selective cyclooxygenase-2 inhibitor, celecoxib, on breast cancer in Vitro and in Vivo
Dai, Zhi-Jun
Ma, Xiao-Bin
Kang, Hua-Feng
Gao, Jie
Min, Wei-Li
Guan, Hai-Tao
Diao, Yan
Lu, Wang-Feng
Wang, Xi-Jing
CANCER CELL INTERNATIONAL, 2012, 12
[43] Plasma MCP-1 levels in bipolar depression during cyclooxygenase-2 inhibitor combination treatment
Edberg, David
Hoppensteadt, Debra
Walborn, Amanda
Fareed, Jawed
Sinacore, James
Halaris, Angelos
JOURNAL OF PSYCHIATRIC RESEARCH, 2020, 129 : 189 - 197
[44] Potential role of cyclooxygenase-2 on the regulation of the drug efflux transporter ABCG2 in breast cancer cell lines
Kalalinia, Fatemeh
Elahian, Fatemeh
Behravan, Javad
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2011, 137 (02) : 321 - 330
[45] Cyclooxygenase-2 in cancer: A review
Goradel, Nasser Hashemi
Najafi, Masoud
Salehi, Eniseh
Farhood, Bagher
Mortezaee, Keywan
JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (05) : 5683 - 5699
[46] The cyclooxygenase-2 inhibitor celecoxib is a potent inhibitor of human carbonic anhydrase II
Knudsen, JF
Carlsson, U
Hammarström, P
Sokol, GH
Cantilena, LR
INFLAMMATION, 2004, 28 (05) : 285 - 290
[47] Effect of cyclooxygenase-2 inhibitor (celecoxib) on the infarcted heart in situ
Yamamoto, T
Kakar, NR
Vina, ER
Johnson, PE
Bing, RJ
PHARMACOLOGY, 2001, 63 (01) : 28 - 33
[48] Cancer and cyclooxygenase-2 (COX-2) inhibition
Evans, JF
Kargman, SL
CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (06) : 627 - 634
[49] The Cyclooxygenase-2 Inhibitor Celecoxib Is a Potent Inhibitor of Human Carbonic Anhydrase II
James F. Knudsen
Uno Carlsson
Per Hammarström
Gerald H. Sokol
Louis R. Cantilena
Inflammation, 2004, 28 : 285 - 290
[50] Editorial Comment to Novel strategy for cystitis glandularis: Oral treatment with cyclooxygenase-2 inhibitor
Takahashi, Satoshi
INTERNATIONAL JOURNAL OF UROLOGY, 2016, 23 (08) : 709 - 709

← 1 2 3 4 5 →